NCT04288232已完成3 期
A Multicenter, Open-label, Prospective, Interventional Study to Assess the Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 45
- 主要终点
- Mean change of best corrected visual acuity (BCVA) from baseline to week 52
研究概览
简要总结
Phase IIIb, multicenter, open-label, prospective, interventional study to assess the potential benefit of Aflibercept treatment administered IVT at a dosage of 2 mg with five monthly loading doses and then treat and extend over 48 weeks, with the primary endpoint as BCVA assessed at Week 52.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults ≥ 20 years old with type 1 or 2 diabetes mellitus
- •Subjects with DME secondary to diabetes mellitus involving the center of the macula (defined as the area of the center subfield of optical coherence tomography [OCT]) in the study eye
- •Retinal thickness as assessed by OCT above (>) 300 um in the study eye
- •BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye
- •Would be able to comply with clinic visits and study-related procedures
- •Would be able to provide a signed informed consent form (ICF)
排除标准
- •Ocular conditions with a poorer prognosis in the fellow eye than in the study eye
- •History of vitreoretinal surgery and/or including scleral buckling in the study eye
- •Laser photocoagulation (pan-retinal or macular) in the study eye within 90 days of Day 1
- •Against the background of a relevant number of previous macular laser treatments the investigator's point of view was that the subjects had no potential to benefit from laser treatments (e.g., if too many laser treatments were applied in the past)
- •Previous use of intraocular or periocular corticosteroids in the study eye within 120 days of Day 1
- •Previous treatment with anti-angiogenic drugs in either eye (pegaptanib sodium, bevacizumab, ranibizumab etc.) within 90 days of Day 1
- •High risk proliferative diabetic retinopathy (PDR) in the study eye upon physician's discretion
- •High risk = the presence of any of the following:
- •Vitreous hemorrhage
- •New vessels on the disk >1/3 disk diameter
- •New vessels elsewhere >1/2 disk diameter
- •History of idiopathic or autoimmune uveitis in the study eye
- •Cataract surgery within 90 days before Day 1 in the study eye
- •Aphakia in the study eye
- •Yttrium-aluminium-garnet (YAG) capsulotomy in the study eye within 30 days before Day 1
- •Any other intraocular surgery within 90 days of Day 1 in the study eye
- •Vitreomacular traction or epiretinal membrane in the study eye evident biomicroscopically or on OCT that is thought to affect central vision
- •Current iris neovascularization, vitreous hemorrhage, or tractional retinal detachment in the study eye
- •Pre-retinal fibrosis involving the macula in the study eye
- •Structural damage to the center of the macula in the study eye that was likely to preclude improvement in BCVA following the resolution of macular edema including atrophy of the retinal pigment epithelium, subretinal fibrosis or scar, significant macular ischemia or organized hard exudates
- •Ocular inflammation including trace or above in the study eye
- •Evidence of infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye
- •Filtration surgery for glaucoma in the past or likely to be needed in the future on the study eye
- •Intraocular pressure (IOP) ≥ 25 mmHg in the study eye
- •High myopia (≤ -6.0 diopters or axial length of ≥26.5 mm) prior to any possible refractive or cataract surgery
- •Concurrent disease in the study eye, other than DME, that could compromise VA, require medical or surgical intervention during the study period, or could confound interpretation of the results (including retinal vascular occlusion, retinal detachment, macular hole, or choroidal neovascularization of any cause)
- •Only 1 functional eye even if that eye was otherwise eligible for the study
- •Ocular media of insufficient quality to obtain fundus and OCT images
- •Current treatment for a serious systemic infection
- •Administration of systemic anti-angiogenic agents within 180 days before Day 1
- •Uncontrolled diabetes mellitus, as defined by Hemoglobin A1c; (glycosylated hemoglobin) (HbA1c)>10%.
- •Uncontrolled blood pressure (defined as systolic >160 mmHg or diastolic >95 mmHg while subject was sitting)
- •History of either cerebral vascular accident and/or myocardial infarction within 180 days prior to Day 1
- •Renal failure requiring dialysis or renal transplant
- •History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, might affect interpretation of the results of the study, or rendered the subject at high risk for treatment complications
- •Pregnant or breast-feeding women
- •Sexually active men or women of childbearing potential who were unwilling to practice adequate contraception during the study were excluded (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly or diaphragm plus contraceptive sponge, foam, or jelly).
- •Allergy to fluorescein
- •Participation in an investigational study within 30 days prior to screening visit that involved treatment with any drug (excluding vitamins and minerals) or device
研究组 & 干预措施
Intravitreal aflibercept
Experimental
Intravitreal injection of aflibercept 2.0mg/0.05 ml Aflibercept was administered with 5 monthly loadings followed by treat-and-extend with a 4-week interval increment/decrement with maxima cap at 12 weeks to visual/anatomic stability.
干预措施: Aflibercept Injection [Eylea] (Drug)
结局指标
主要结局
Mean change of best corrected visual acuity (BCVA) from baseline to week 52
时间窗: baseline to week 52
BCVA is measured by ETDRS chart
次要结局
- Mean change in central subfoveal thickness (CST) from baseline to week 52.(baseline to week 52)
- Mean/medium number of injection from baseline to week 52(baseline to week 52)
- Proportion of subjects who gained > 15 ETDRS letters from baseline to week 52(baseline to week 52)
- Proportion of subjects demonstrating retina dry at week 20 and week 52(week 20 and week 52)
- Proportion of subjects with > 2-step improvement in DRSS from baseline to week 52(baseline to week 52)
研究者
相似试验
已完成
3 期
To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.HER2-ve Metastatic Breast CancerGermline BRCA1/2 MutationsSomatic BRCA1/2 MutationsNCT03286842AstraZeneca256
已完成
3 期
4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast CancerMetastatic Breast CancerNCT01626222Novartis Pharmaceuticals301
已完成
3 期
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic LeukemiaLymphocytic Leukemia, ChronicNCT02242942Hoffmann-La Roche445
已完成
3 期
Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes MellitusType 2 Diabetes MellitusType 1 Diabetes MellitusNCT00108004AstraZeneca400
已完成
3 期
A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.Rheumatoid ArthritisNCT02011334Hoffmann-La Roche285